GLP-1 gastroparesis affects 4-fold more patients than placebo groups , with non-diabetic users facing 3.33 times higher risk than alternative weight loss treatments Short-acting GLP-1s cause more severe gastric slowing than long-acting versions , delaying emptying by 52 minutes versus 25 minutes respectively Retained gastric contents occur in 13.6% of GLP-1 users versus 2.3% of non-users , creating dangerous aspiration risks during medical procedures Most GLP-1 gastroparesis cases are reversible through tachyphylaxis , with gastric emptying effects diminishing within 4-6 weeks of continuous use Pre-procedural fasting protocols must be extended for GLP-1 users , holding daily medications on procedure day and weekly doses seven days before surgery The condition requires careful differentiation from functional dyspepsia and mechanical obstruction, as proper diagnosis directly impacts treatment outcomes
The Results Steady weight loss was obtained over the course of 7 months to get him to his goal weight of 190 pounds
Do they really work
Studies have found that GLP-1 receptor is not only expressed in islet cells, but also widely distributed in brain, lung, gastrointestinal tract, kidney, liver, heart and other organs in the body
doi:10.1016/0009-2797(91)90033-4.
Can BPC-157 be used in human clinical trials
